L'intérêt à découvert pour Cullinan Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Cullinan Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Cullinan Therapeutics (NASDAQ:CGEM) Stock, Rapport sur les intérêts à découvert

Cullinan Therapeutics

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics Inc

Capgemini SE

News

Guidance

Kontoor Brands Sees FY25 Revenue Of $2.63B - $2.69B Vs. $2.6B Est; Adj EPS Of $5.20 - $5.30 Vs. $5.37 Est.

Wedbush analyst Nick Setyan reiterates Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Outperform and maintains $500 price target.

Price Target

Reiteration

Analyst Ratings

Wedbush Reiterates Outperform on Domino's Pizza, Maintains $500 Price Target

Barclays analyst Eddie Kim maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Equal-Weight and lowers the price target from $49 to $46.

Barclays Maintains Equal-Weight on Valaris, Lowers Price Target to $46

Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) declined 5.1% in the pre-market trading session on Tuesday after Bitcoin plummeted over 7% in the last 24 hours, according to data from <a href="http://pro.benzinga.com">Benzinga Pro.</a> 
What Happened: MSTR on Monday added nearly $2 billion worth of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to its holdings, bringing its total close to 500,000 BTC. 
Strategy, previously known as MicroStrategy, revealed in a regulatory filing that it has acquired an additional 20,356 Bitcoins at an average price of $97,514 per Bitcoin between Feb. 18 and Feb. 23, achieving a year-to-date BTC Yield of 6.9%. 
The purchase was financed through a zero-coupon convertible note offering.
Strategy&#8217;s BTC Yield—a key metric tracking the percentage change in the ratio of bitcoin holdings to assumed diluted shares outstanding—rose to 6.9% between Jan. 1 and Feb. 23. As of Feb. 23, Strategy&#8217;s total Bitcoin holdings reached 499,096, an increase from 447,470 at the close of 2024.
Strategy&#8217;s Executive Chairman, Michael Saylor, had previously hinted at the purchase on the X platform. The company has been making weekly Bitcoin purchases since November, with the latest being the largest since December 9.
On Monday, Strategy&#8217;s shares fell by&nbsp;nearly 4% in late trading, but&nbsp;the stock still surged&nbsp;more than 300% over the&nbsp;past 12 months. Bitcoin was trading below $95,000, significantly lower than its all-time high of approximately $109,000 reached last month.
SEE ALSO: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43934933/bitcoin-plunges-below-88000-what-is-going-on">Bitcoin Plunges Below $88,000: What Is Going On?</a>
Why It Matters: Despite the aggressive Bitcoin accumulation strategy boosting its stock market capitalization significantly, critics remain skeptical over the long-term sustainability of this approach. Influential economist and market commentator Peter Schiff <a href="https://www.benzinga.com/25/02/43931332/peter-schiff-questions-michael-saylor-led-strategys-leverage-bitcoin-play-amid-share-price-decline-massive-dilution-has-destroyed-shareholder-value">criticized the company&#8217;s</a> debt-fueled bitcoin purchases, highlighting the decline in the firm's share price and the narrowing Net Asset Value premium.
Despite Strategy&#8217;s co-founder Michael Saylor saying that his leveraged Bitcoin buys generated a yield of 6.9% this year, Schiff pointed out that the stock value has dropped by 6%. Schiff argued that the "massive dilution" has destroyed shareholder value, causing the premium to its Bitcoin holdings to collapse by 85%.
Notably, on Friday, Saylor met with the Securities And Exchange Commission&#8217;s (SEC) Crypto Task Force and discussed regulatory reforms in the U.S. while safeguarding crypto holders&#8217; rights. He also presented his strategic <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43920916/michael-saylor-presents-digital-assets-framework-to-sec-crypto-task-force">Bitcoin reserve plan</a> to&nbsp;the SEC aiming to create between $16 billion to $81 trillion in wealth for the US Treasury.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43931003/cathie-woods-ark-invest-makes-amazon-bet-in-monday-market-splash">Cathie Wood&#8217;s Ark Invest Makes Amazon Bet in Monday Market Splash</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

MSTR

MSTR Stock Falls Over 5% In Tuesday Pre-Market: What's Going On?

HC Wainwright &amp; Co. analyst Sameer Joshi initiates coverage on Centrus Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LEU#AMEX">LEU</a>) with a Buy rating and announces Price Target of $300.

Initiation

HC Wainwright & Co. Initiates Coverage On Centrus Energy with Buy Rating, Announces Price Target of $300

Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $1.34 by 2.99 percent. This is a 2.22 percent increase over earnings of $1.35 per share from the same period last year. The company reported quarterly sales of $699.28 million which beat the analyst consensus estimate of $698.07 million by 0.17 percent. This is a 4.40 percent increase over sales of $669.80 million the same period last year.

Earnings

Earnings Beats

Kontoor Brands Q4 Adj $1.38 Beats $1.34 Estimate, Sales $699.28M Beat $698.07M Estimate

Barclays analyst David Anderson maintains Transocean (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) with a Overweight and lowers the price target from $4.5 to $4.

Barclays Maintains Overweight on Transocean, Lowers Price Target to $4

LVTX

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

General

NEOV

NeoVolta Completes Phase Two Of Its Loan Application For $300M From The US Department Of Energy

Needham analyst Mayank Tandon maintains EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) with a Buy and raises the price target from $30 to $38.

EVER

Needham Maintains Buy on EverQuote, Raises Price Target to $38

TopBuild announced today that its Board of Directors authorized the repurchase of up to $1.0 billion of the Company's outstanding common stock. The new authorization is in addition to the $188.1 million remaining from the prior authorization (as of December 31, 2024), bringing total availability for share repurchases to $1.2 billion. The authorization reflects the continued confidence of management and the Board in TopBuild's long-term strategy and demonstrates the Company's commitment to returning capital to shareholders.

Buybacks

TopBuild Authorized The Repurchase Of Up To $1.0B, Which Is In Addition To The $188.1M Remaining From The Prior Authorization (As of December 31, 2024)

Barclays analyst Matthew Bouley maintains Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) with a Underweight and lowers the price target from $115 to $101.

Barclays Maintains Underweight on Toll Brothers, Lowers Price Target to $101

Brazil Potash Subsidiary Potássio do Brasil Receives Approval To Begin Fauna Rescue and Vegetation Suppression Activities In The Mine Area Of The Autazes Potash Project

TopBuild Sees FY25 Sales Of $5.05B-$5.35B Vs. $5.465B and Adj EBITDA Of $925M-$1.075B

Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA&#xAE; (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, then continued as adjuvant treatment in combination with standard of care radiotherapy with or without cisplatin and then as a single agent. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 23, 2025.
The sBLA is based on data from the Phase 3 KEYNOTE-689 trial. Results from a pre-specified first interim analysis, which will be presented at an upcoming medical meeting, showed that in patients with resectable LA-HNSCC, the KEYTRUDA perioperative treatment regimen demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) compared to adjuvant radiotherapy (with or without cisplatin) alone. The study also showed a statistically significant improvement in major pathological response (mPR), a key secondary endpoint, for patients in the KEYTRUDA arm compared with adjuvant radiotherapy alone. The safety profile of KEYTRUDA was consistent with that observed in previously reported studies; no new safety signals were identified.

Government

Regulations

Merck's Keytruda Gains FDA Priority Review for Head and Neck Cancer Treatment

Barclays analyst Nicholas Campanella maintains OGE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGE#NYSE">OGE</a>) with a Equal-Weight and raises the price target from $42 to $44.

Barclays Maintains Equal-Weight on OGE Energy, Raises Price Target to $44

Castellum GTMR Subsidiary Selected As Special Compartmented Information Multiple Award Contract (SCI MAC) Vendor

WIIM

DNUT

Krispy Kreme shares are trading lower after the company reported worse-than-expected Q4 earnings and issued weak FY25 guidance.

TopBuild (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) reported quarterly earnings of $5.13 per share which beat the analyst consensus estimate of $5.05 by 1.58 percent. This is a 9.38 percent increase over earnings of $4.69 per share from the same period last year. The company reported quarterly sales of $1.31 billion which met the analyst consensus estimate. This is a 2.04 percent increase over sales of $1.29 billion the same period last year.

TopBuild Q4 2024 Adj EPS $5.13 Beats $5.05 Estimate, Sales $1.31B Inline

HC Wainwright &amp; Co. analyst Mike Colonnese reiterates Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) with a Buy and maintains $17 price target.

RIOT

HC Wainwright & Co. Reiterates Buy on Riot Platforms, Maintains $17 Price Target

Press Releases

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Health Care

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Clear Street Launches Healthcare & Biotechnology Equity Research

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

Comments

Cullinan Therapeutics

Intérêt court

Cullinan Therapeutics (NASDAQ:CGEM) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL